Excerpt: With AMTAGVI, Iovance has a first-in-class TIL therapy on the market — so the story shifts from 'will it get approved' to 'can they execute the commercial ramp and manufacturing at scale' while managing cash. The hub covers AMTAGVI, the TIL-therapy platform, the commercial-execution questions and the main risks.
Full write-up (free, no signup): https://www.merlintrader.com/iovance-biothera...stock-hub/
Not financial advice — just research.